David earned a PhD in Biological Sciences from Columbia University in New York, NY, where he studied how Drosophila ovarian adult stem cells respond to cell signaling pathway manipulations. This work helped to redefine the organizational principles underlying adult stem cell growth models. He is currently a Science Writer, as part of the BioNews Services writing team.
Using Cymerus mesenchymal stem cells (MSCs) to treat idiopathic pulmonary fibrosis (IPF) resulted in dramatic reductions in IPF symptoms and significant improvements in lung functionality in an animal model of ... Read more
The nonprofit Three Lakes Foundation has teamed with Matter, a healthcare incubator, to launch the PF Innovation Challenge, an effort to promote better ways of diagnosing pulmonary fibrosis (PF) and caring ... Read more
AstraZeneca has acquired a global license for RXC006, an investigational porcupine inhibitor for treating fibrotic diseases, including idiopathic pulmonary fibrosis (IPF), providing $17 million in initial funding to the therapy’s developer ... Read more
A drop in air pollution due to COVID-19 restrictions has eased overall symptoms for about one in every six people diagnosed with respiratory disorders, a British Lung Foundation (BLF) survey of ... Read more
A significant proportion of people with idiopathic pulmonary fibrosis (IPF) were found to have the sleep disorder restless legs syndrome (RLS), compared to a control group, according to new research. ... Read more
The Pulmonary Fibrosis Foundation (PFF) and Celgene, a subsidiary of Bristol-Myers Squibb, are leading a collaboration with the long-term goal of streamlining the development of targeted treatment strategies for ... Read more
Pin It on Pinterest